A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs TG 1050 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Transgene
- 17 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to a Transgene media release.
- 13 Sep 2017 According to a Transgene media release, results from the first part of the study will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting (Oct 2017).
- 17 Oct 2016 According to Transgene media release, First Patient Randomized in Multiple Dose Cohort and first data readout is expected in second half of 2017.